Direct Biologics Announces Publication of Significant Survival Benefit with ExoFlo™ in its Phase 2 Randomized Controlled Clinical Trial in the Journal CHEST July 12, 2023 08:00 AM Eastern Daylight Time AUSTIN, Texas–(BUSINESS…

Direct Biologics Receives FDA Clearance to Initiate Phase 1b/2a Clinical Trial of ExoFlo™ in Patients with Medically Refractory Perianal Fistulizing Crohn’s Disease ExoFlo is the first extracellular vesicle therapeutic candidate…

Direct Biologics Reports Compelling Data as ExoFlo™ Expanded Access Program in Hospitalized COVID-19 Patients with Moderate-to-Severe ARDS Surpasses 100 Subjects Company’s Phase 3 EXTINGUISH ARDS trial is enrolling hospitalized patients with…

Direct Biologics Announces FDA Authorization to Expand Ongoing Phase 3 Clinical Study of ExoFlo™ to All-Cause Moderate-to-Severe ARDS Ongoing pivotal Phase 3 EXTINGUISH ARDS trial expands to enroll hospitalized patients…

March 28, 2023 08:00 AM Eastern Daylight Time AUSTIN, Texas–(BUSINESS WIRE)–Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) derived from bone marrow…

Direct Biologics Announces Initiation of Phase 1 Clinical Trial for Medically Refractory Crohn’s Disease First patient dosed with ExoFlo™ in open-label trial March 21, 2023 08:00 AM Eastern Daylight Time AUSTIN,…

Direct Biologics Reports Compelling Results From Phase 2 Trial With ExoFlo™ in Hospitalized Patients With Respiratory Failure or Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Relative risk reduction…

FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial AUSTIN, Texas, April 21, 2022 Direct Biologics, a regenerative biotechnology company with a…

FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS AUSTIN, Texas, April 12, 2022 Direct Biologics, an innovative biotechnology company…

Direct Biologics Reveals Successful Outcomes from EXIT COVID-19 Phase II Clinical Trial AUSTIN, Texas, April 6, 2022 Direct Biologics, a regenerative biotechnology company with a lifesaving mesenchymal stem cell (MSC)…